Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) saw some unusual options trading activity on Wednesday. Investors acquired 41,901 put options on the stock. This represents an increase of 3,838% compared to the typical volume of 1,064 put options.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $0.26 on Friday. Heron Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.57. The firm has a market capitalization of $50.25 million, a price-to-earnings ratio of -2.20 and a beta of 1.65. The company has a debt-to-equity ratio of 32.59, a quick ratio of 1.31 and a current ratio of 2.33. The stock’s 50-day simple moving average is $0.32 and its 200-day simple moving average is $0.63.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $35.25 million during the quarter, compared to analyst estimates of $37.50 million. Heron Therapeutics had a negative net margin of 14.55% and a negative return on equity of 277.36%. As a group, equities analysts forecast that Heron Therapeutics will post -0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC acquired a new position in shares of Heron Therapeutics in the 1st quarter valued at $7,855,000. BlackRock Inc. acquired a new stake in Heron Therapeutics during the 2nd quarter worth about $4,503,000. Tejara Capital Ltd acquired a new stake in Heron Therapeutics during the 2nd quarter worth about $2,779,000. Pale Fire Capital SE lifted its position in Heron Therapeutics by 84.8% during the 1st quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock worth $2,173,000 after acquiring an additional 1,246,673 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Heron Therapeutics during the 2nd quarter valued at about $445,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on HRTX shares. Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, HC Wainwright cut Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $2.00.

View Our Latest Analysis on HRTX

Heron Therapeutics Company Profile

(Get Free Report)

Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients in acute care settings, including cancer treatment and surgery. Its work includes medicines intended to prevent nausea and vomiting associated with chemotherapy and surgery, as well as treatments for postsurgical pain. Heron’s products include CINVANTI and APONVIE, injectable formulations of aprepitant used to help prevent nausea and vomiting in specified clinical settings. The company also developed ZYNRELEF, a combination of bupivacaine and meloxicam for postsurgical pain, and SUSTOL, an extended-release formulation of granisetron for chemotherapy-related nausea and vomiting.

Featured Stories

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.